Sanofi closes deal on Acambis
Sanofi-Aventis closes on its deal to buy Acambis today, but it's working hard to avoid losing the entrepreneurial spirit that attracted the French pharma company to the vaccine developer in the first
Crucell inks licensing deal; HPV vaccine requirement triggers protests;
Vaccine Research Crucell will pocket a $2.5 million upfront fee and up to $30 million in milestones after inking an exclusive licensing deal with North Carolina-based Talecris Biotherapeutics for an
Sanofi Pasteur begins melanoma vaccine trial
Sanofi pasteur is mounting a mid-stage trial involving 120 patients at 23 centers to test the efficacy of a new melanoma vaccine. The vaccine uses a modified canarypox virus containing the genes for
Transgene shares up on positive cancer vax data
Shares of France's Transgene jumped about 10 percent on Monday after new data from a Phase IIb trial of TG4010 demonstrated a survival benefit for non-small cell lung cancer patients. The French
Experimental vax targets aggressive tumors
A new vaccine that targets HER2-positive tumor cells was successful in eliminating tumors in laboratory animals. And researchers say that the vaccine may well stop cancer from reoccurring in women or
Vaccine expert's autism defense triggers reaction
When vaccine expert Paul Offit released his new book defending vaccines against the attacks of critics claiming a link to autism, he had a new security system installed at his house. Rates of autism
Australian wins prize for vaccine; 1918 epidemic may be key to preventing new outbreaks;
Proteins targeted in hunt for universal flu jab
Scientists at Oxford University are testing a new universal flu vaccine that targets the internal proteins of the virus, which change very little from one strain to the next. The Phase I trial
Despite concerns, vaccination rates still high
There's been quite an uproar this year over the supposed safety risks presented by vaccines and concerns that a number of parents are avoiding the jab to protect their children. But the CDC--which
Novartis' MenB vaccine protects infants
A fresh batch of trial data indicates that the Novartis Meningitis B vaccine protects infants six months and older against multiple strains of potentially deadly meningococcal B bacteria. More than
Research team finds key to MRSA vaccine
A team of top vaccine researchers say that the key to coming up with an effective vaccine to guard against MRSA has been found in the 'sticky glue' the bacteria produces to grow as a biofilm. Staph
Oxford researchers develop universal flu vax
Oxford University researchers have developed a universal flu vaccine using a potentially revolutionary approach. Traditional flu vaccines are designed to prompt an immune system response to proteins
Chicken pox vax effective, ignored; Merck launches mid-stage Staph vaccine trial;
Experts say allergies no reason to stop vaccinations
A new study from Johns Hopkins Children's Center says that with close monitoring and some standard precautions even children with known vaccine allergies can be vaccinated safely. Generally, there
What's stopping girls from getting the HPV jab?
The controversial HPV vaccine has been making only slow progress in the U.S. Despite the fact that half of all girls are exposed to the virus--and 4,000 die each year from the cancer that it
Analysts buoy Cell Genesys' hope for GVAX
Shares of Cell Genesys got hit hard last week after the company announced that it was
Study: No link between measles vaccine and autism
One of the biggest issues in the vaccine world is an underlying fear in the general population that a vaccination can trigger autism. Concerns about a link are driving large numbers of parents to
Chickenpox vax program a success
Reports of chickenpox have drastically declined as a result of the national vaccination program implemented in the 1990s. In a study published in the journal Pediatrics today, CDC researchers report
Waiver 'pockets' raise outbreak fears; Merck launches mid-stage Staph vaccine trial;
Vaccine Market In Oregon, public health officials have identified various communities in the state where there's a high number of parents opting out of the vaccines required for children. And the
Cell Genesys' cancer vax setback depresses field
Back in 2000, shares of Cell Genesys traded at more than $50 a share. Yesterday, the stock closed under $1 after plummeting more than 70 percent after its prostate cancer vaccine trial was halted due
